Trial Profile
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study of 100 or 250 µg of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jun 2015
Price :
$35
*
At a glance
- Drugs Nicotine abuse vaccine (Primary)
- Indications Smoking withdrawal; Substance-related disorders
- Focus Therapeutic Use
- Sponsors Celtic Pharma
- 31 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 May 2009 New trial record